The recent discovery of metabolic roles for fibroblast growth factor 1 (FGF1) in glucose homeostasis has expanded the functions of this classically known mitogen. To dissect the molecular basis for this functional pleiotropy, we engineered an FGF1 partial agonist carrying triple mutations (FGF1 DHBS ) that diminished its ability to induce heparan sulfate (HS)-assisted FGF receptor (FGFR) dimerization and activation. FGF1
SUMMARY
The recent discovery of metabolic roles for fibroblast growth factor 1 (FGF1) in glucose homeostasis has expanded the functions of this classically known mitogen. To dissect the molecular basis for this functional pleiotropy, we engineered an FGF1 partial agonist carrying triple mutations (FGF1 DHBS ) that diminished its ability to induce heparan sulfate (HS)-assisted FGF receptor (FGFR) dimerization and activation. FGF1
DHBS exhibited a severely reduced proliferative potential, while preserving the full metabolic activity of wild-type FGF1 in vitro and in vivo. Hence, suboptimal FGFR activation by a weak FGF1-FGFR dimer is sufficient to evoke a metabolic response, whereas full FGFR activation by stable and sustained dimerization is required to elicit a mitogenic response. In addition to providing a physical basis for the diverse activities of FGF1, our findings will impact ongoing drug discoveries targeting FGF1 and related FGFs for the treatment of a variety of human diseases.
INTRODUCTION
The mammalian fibroblast growth factor (FGF) family comprises 15 paracrine-acting and three endocrine-acting ligands that signal through four FGF receptor tyrosine kinases (FGFR1-FGFR4) and their alternatively spliced isoforms to govern a plethora of essential functions in mammalian development, metabolism, and tissue homeostasis Goetz and Mohammadi, 2013; Itoh and Ornitz, 2011) . Paracrine FGFs require heparan sulfate (HS) glycosaminoglycans to bind, dimerize, and activate their cognate FGFRs (Mohammadi et al., 2005; Olsen et al., 2006; Yeh et al., 2003) . Owing to major structural distortions in their HS binding sites, however, the endocrine FGFs (FGF19, FGF21, and FGF23) interact poorly with HS and hence rely on Klotho coreceptors to bind, dimerize, and activate their cognate FGFRs Goetz and Mohammadi, 2013; Kurosu et al., 2007; Ogawa et al., 2007; Urakawa et al., 2006) . HS-or Klotho-dependent dimerization of extracellular domains of FGFR by paracrine or endocrine FGFs juxtaposes the cytoplasmic tyrosine kinase domains in correct orientation/proximity to facilitate activation loop (A-loop) tyrosine transphosphorylation resulting in the activation of intracellular kinase domains (Mohammadi et al., 1996) . This in turn leads to phosphorylation of intracellular substrates and activation of multiple downstream signaling pathways (Eswarakumar et al., 2005; Lemmon and Schlessinger, 2010; Schlessinger and Lemmon, 2003) . Despite exerting pleiotropic functions, all FGFs rely on a common set of intracellular pathways including PLCg/PKC, FRS2a/RAS-MAPK, Gab1/PI3 kinase/Akt, and CrkL/Cdc42-Rac pathways (Dailey et al., 2005; Eswarakumar et al., 2005; Kouhara et al., 1997; Larsson et al., 1999; Seo et al., 2009) . Hence, the underlying molecular mechanisms of signaling specificity and/or diversity have remained elusive.
To gain insights into the molecular mechanisms regulating FGF signaling specificity/diversity, in this report, we analyzed the large body of accumulated structural data in our laboratory that includes eight binary paracrine FGF-FGFR complexes, an HS-assisted 2:2 FGF-FGFR dimer, and two endocrine FGFs (Beenken and Mohammadi, 2012; Goetz and Mohammadi, 2013) . This analysis led us to posit a model whereby different biological responses of FGFs are manifestations of different thresholds in FGF-FGFR binding/dimerization, with corresponding differences in FGFR transphosphorylation and activation. We tested our working model using FGF1, the founding member of the FGF family that is best known for its mitogenic activity on cells from a variety of tissue origins including liver, vasculature, and skin (Kan et al., 1989; Nabel et al., 1993; Wied1ocha et al., 1996) . Recently, Jonker et al. (2012) discovered an unexpected metabolic role for FGF1 as a critical transducer of PPARg signaling that mediates the proper coupling of nutrient storage to adaptive remodeling of adipose tissue. In a followup study, we showed that administration of exogenous FGF1 stimulates glucose uptake in an insulin-dependent fashion, much like the endocrine-acting non-mitogenic FGF21 (Suh et al., 2014) . The mixed mitogenic and metabolic activities of FGF1 make this ligand an ideal paradigm for dissecting the role of FGF-FGFR dimer stability in differentiating mitogenic versus metabolic functions of FGFs. Based on our detailed structural insights into HS-assisted paracrine FGF-FGFR dimerization (Mohammadi et al., 2005; Schlessinger et al., 2000) , an FGF1 variant, termed FGF1 DHBS , with suppressed ability to induce HS-dependent FGFR dimerization was engineered. Detailed analysis of the mitogenic and metabolic properties of this FGF1 variant showed that it has greatly reduced proliferative potency and efficacy while retaining full metabolic efficacy of wild-type FGF1 (FGF1 WT ) both in vitro and in vivo. These data support our hypothesis that differences in FGF-FGFR binding affinity and dimer stability translate into differences in the magnitude of intracellular signals emanating from FGFRs to determine mitogenic versus metabolic cellular responses. Moreover, the results from this study pave the way for engineering safer FGF1 and other FGFs that solely possess metabolic activity.
RESULTS AND DISCUSSION
Structural Analysis Identifies a Link between 1:1 FGF-FGFR Binding Affinity and 2:2 Dimer Stability and Differential Biological Activity of FGFs The existence of a relationship between the strength of FGF-FGFR binding/dimerization and the divergent biological activities of FGFs was first inferred from our structural exploration of the functional dichotomy of FGF8 isoforms. FGF8a and FGF8b are two alternatively spliced FGF8 isoforms that share an identical FGFR binding specificity profile yet elicit markedly different tissue patterning outcomes during brain development (Joyner et al., 2000) . Through solving the crystal structure of FGF8b in complex with FGFR2c, we previously traced the difference in the brain patterning activities of FGF8a and FGF8b to a difference in binding affinities of these FGF8 isoforms for FGFR (Olsen et al., 2006) . Specifically, a single residue (Phe-32) from the alternatively spliced N terminus of FGF8b was shown to make hydrophobic contacts with D3 of FGFR, which explains the over one order of magnitude greater receptor binding affinity of FGF8b compared to FGF8a (Olsen et al., 2006) (PDB: 2FDB) ( Figure 1A ). We then showed that mutation of Phe-32 to alanine converts FGF8b to an FGF8a-like molecule with regard to FGFR binding affinity and morphogenetic potential (Olsen et al., 2006) . Because 2:2 FGF-FGFR dimer stability is directly proportional to 1:1 FGF-FGFR binding affinity, these data suggest that FGF8b forms a more robust 2:2 FGF-FGFR dimer than FGF8a, which in turn implies that FGF8b is more potent in inducing FGFR transphosphorylation and activation than FGF8a. Moreover, because FGFR activation is a prerequisite for intracellular substrate phosphorylation and activation of downstream pathways, it follows that FGF8b should be transmitting robust/persistent signals, whereas intracellular signals of FGF8a should be weak and transient. These observations led us to postulate that differences in Figure 1 . The Differences in the Stabilization of 2:2 FGF-FGFR Dimers Induced by FGF8 Isoforms (A) Cartoon representation of the crystal structure of the FGF8b-FGFR1c complex based on the crystal structure of the FGF8b-FGFR2c complex (PDB: 2FDB) (Olsen et al., 2006 ) to promote HS-assisted FGFR1c dimerization in vitro. As shown in Figure 1B , FGF8b exhibited a greater capacity than FGF8a to dimerize the FGFR1c. Mutation of Phe-32 to alanine converted FGF8b to an FGF8a-like molecule with regard to FGFR binding affinity ( Figure S1A ) and FGFR dimerization capacity ( Figure 1B) . We further compared the stability of FGF8a-FGFR1c, FGF8b-FGFR1c, and FGF8b Figure 1D ). Comparative structural analysis of the paracrine and endocrine FGFs further emphasizes the notion that differences in the strength of FGF-FGFR binding and dimerization could underlie the divergent biological activities of FGFs. Modeling of endocrine FGF-FGFR complexes based on the crystal structures of paracrine FGF-FGFR complexes as templates reveals replacements of at least one residue in the respective receptor binding site of endocrine FGFs with residues that are less optimal for receptor binding (Figures 2A and 2B ). Consistent with these structural observations, binding of endocrine FGFs to FGFR is barely detectable in vitro (Ibrahimi et al., 2004; Kharitonenkov et al., 2005; Mohammadi et al., 2005; Yie et al., 2009 ). This structural analysis implies that compared to paracrine FGFs such as FGF1, endocrine FGFs should have weaker ability in dimerizing and activating FGFRs and correspondingly should have weaker capacity to activate intracellular signaling pathways. To test our structural prediction, the lentiviral expression system was used to establish two BaF3 cell lines that ectopically co-express FGFR1c (a cognate FGFR for all three endocrine FGFs) and the full-length transmembrane form of aKlotho (coreceptor for FGF23) or bKlotho (coreceptor for FGF19 and FGF21 showed that at both doses tested, all three endocrine FGFs were weaker than FGF1 WT in inducing phosphorylation of FGFR1c on the kinase A-loop tyrosines and downstream MAPK phosphorylation ( Figures 2C-2E ). Importantly, compared to paracrine FGFs such as FGF1 that are potent mitogens for a variety of cell types, the endocrine FGFs completely lack (FGF21) or have poor mitogenic activity (FGF19) ( Figure S2A ), which is consistent with previously published data (Kharitonenkov et al., 2005; Nakamura et al., 2011; Ornitz et al., 1996; Suzuki et al., 2008; Zhang et al., 2006a) . The higher mitogenic activity of FGF19 than FGF21 is congruent with the higher FGFR binding affinity of FGF19 relative to FGF21 (Wu et al., 2010) .
Taken together, these data substantiate the existence of a direct link between the strength/stability of FGF-FGFR binding/ dimerization and the selection of cellular outcome. Our results lead us to propose that while mitogenic activity would require strong FGF-FGFR binding and persistent dimerization, a metabolic response could be achieved with a weak FGF-FGFR binding and transient receptor dimerization.
The Metabolic Effect of FGF1 Can Be Uncoupled from Its Mitogenic Activity FGF1, a classical FGF mitogen, was recently shown to also possess metabolic activity similar to the non-mitogenic, endocrine FGF21 (Suh et al., 2014) . The mixed mitogenic and metabolic activities of FGF1 make this ligand an ideal paradigm for directly testing our hypothesis on the role of FGF-FGFR dimer stability in determination of cellular outcome. We and others have previously shown that in the absence of HS, the affinities of paracrine FGFs for their cognate FGFR are below the threshold necessary to induce sustained receptor dimerization (Delehedde et al., 2002; Makarenkova et al., 2009; Mohammadi et al., 2005; Schlessinger et al., 2000) . HS simultaneously engages the HS binding sites of FGF and FGFR simultaneously with a resulting enhancement of 1:1 FGF-FGFR binding and stabilization of 2:2 FGF-FGFR dimers (Mohammadi et al., 2005; Schlessinger et al., 2000) . Guided by our structural insights on HS-assisted FGF-FGFR dimerization ( Figure 3A ), we decided to engineer an FGF1 variant with a diminished ability to promote HS-assisted FGFR dimerization. To this end, three key residues from the HS-binding site of FGF1 (namely Lys127, Lys128, and Lys133) were replaced with residues that are less optimal for HS binding (Lys127Asp, Lys128Gln, and Lys133Val; termed FGF1 DHBS ) ( Figure 3B ). We postulated that as a result of compromised HS-binding affinity, FGF1 DHBS should possess a weaker ability to promote HS-assisted FGFR dimerization and should therefore transmit weaker intracellular signals compared to the wild-type parent molecule. To confirm our structural prediction, biotinylated heparin (a surrogate for HS) was captured onto a streptavidin containing surface plasmon resonance (SPR) biosensor chip, and increasing concentrations of FGF1
WT and FGF1 DHBS were passed over the chip. SPR spectroscopy data confirmed that the FGF1 DHBS mutant sustained a substantial loss in HS binding affinity ( Figure 3C close to the theoretical MW of 42.8 kDa ( Figure S3A ). As shown in Figure 3D , the HS decasaccharide caused stoichiometric dimerization of the FGF1 WT -FGFR1c complex. The MW of the onto FGF9 in the FGF9-FGFR1c complex (PDB ID 5W59) (Liu et al., 2017) . The FGF9-FGFR1c complex was chosen for generating the FGF23-FGFR1c model due to comparable receptor-binding specificity of FGF9 and FGF23. Left: whole view of the structural model and close-up view of contacts made between the FGF core region and FGFR1c-D3. Note that substitution of V102 of FGF9 with A80 in FGF23 will result in weakening of a hydrophobic contact with FGFR1c. Right: whole view of the structural model and close-up view of contacts made between the FGF9-N terminus and FGFR1c-D3. Note that substitution of R62 a highly conserved residue among paracrine FGFs in FGF9 with glycine (where it occurs in FGF23) will result in loss of contacts with FGFR1c.
(B) Model of FGF19 bound to FGFR1c generated by superimposing free FGF19 (PDB: 2P23) onto FGF9 in the FGF9-FGFR1c complex (PDB: 5W59) (Liu et al., 2017) . The FGF9-FGFR1c complex was selected for generating the structural model because of the similarity in receptor-binding specificity of FGF9 and FGF19. Moreover, FGFR1c is known to mediate the effects of FGF19 and its close homolog FGF21 on glucose metabolism in adipocytes. Left: whole view of the structural model and close-up view of hydrophobic contacts made between I98 in the b4 strand of FGF9 and V316 in the bC 0 -bE loop of FGFR1c-D3.
Note that substitution of I98 of FGF9 with lysine (present in FGF19) will result in loss of hydrophobic contacts with FGFR1c contributing to poor FGF19-FGFR1c binding. Right: whole view of the structural model and close-up view of contacts made between the b4-b5 loop and FGFR1c-D3. Note that substitution of G103 of FGF9 (a fully conserved residue among paracrine FGFs) with arginine (present in FGF19) introduces steric conflicts with the bF-bG loop in FGFR1-D3 as because of a clash between the molecular surfaces of R88 of FGF19 and S346 of FGFR1c. Moreover, this substitution also causes flipping of the peptide bond linking L87 and R88, which displaces the side chain of L87 away from L349 of FGFR1c, further weakening the FGF19-FGFR1c binding. We next compared the mitogenic potencies of FGF1 WT and FGF1 DHBS using NIH 3T3 fibroblasts, which are known to endogenously express several FGFR isoforms including FGFR1c (Li et al., 1994) . As shown in Figure 3F, Figure 3G ). In agreement with the receptor phosphorylation data, FGF1 DHBS had a diminished ability to induce FRS2a phosphorylation, a major substrate of FGFRs on tyrosine 196, a Grb2-SOS recruitment site, and downstream ERK activation ( Figure 3G ). We further compared the stability of cell surface FGF-FGFR dimers induced by FGF1 WT and FGF1 DHBS by analyzing the intensity and duration of FGFR phosphorylation on A-loop tyrosines and activation of downstream FRS2a/ERK pathway kinetically. As shown in Figure 3H , treatment of cells with FGF1 WT led to the appearance of a signal for A-loop tyrosine phosphorylated FGFR as early as 2 min and the signal continued to intensify until 15 min. By 30 min, the signal intensity diminished but still remained above that observed in the vehicle-treated cells. Figures 4C and 4D) . Apparently, the amplitude/ strength of FGFR activation and ensuing downstream intracellular signaling generated by FGF1 DHBS , which is comparable to Figure 6A ). Moreover, this effect was dosedependent in both FGF1 WT and FGF1 DHBS treatment groups ( Figure 6B ), consistent with previously published data (Suh et al., 2014 (Suh et al., 2014) , FGF1 DHBS caused sustained glucose lowering ( Figure 6G ) with minimal changes in body weight ( Figure 6H ). Notably, both FGF1 WT and FGF1 DHBS were able to normalize blood glucose levels in db/db mice after 4 weeks of treatment ( Figure 6G ). Importantly, as previously shown for FGF1 WT (Suh et al., 2014) 
, FGF1
DHBS did not induce hypoglycemia in both normoglycemic (healthy) chow-fed mice ( Figure S4A ) and diabetic mice even at a high dose ( Figures S4B and S4C ). FGF1 DHBS had no effect on blood glucose levels in streptozotocin (STZ)-induced type 1 diabetic mice demonstrating that FGF1 DHBS mediates its glucose-lowering effects in an insulin-dependent fashion ( Figure S4D ). Hepatic glycogen synthesis and breakdown play an important role in modulating blood glucose levels (Saltiel and Kahn, 2001) . Accordingly, the effect of chronic treatment of FGF1 WT and FGF1 DHBS on hepatic glycogen levels was determined using periodic acid-Schiff staining (PAS) and a colorimetric assay. As shown in Figures S5A and S5C , compared to their lean littermates (db/m), db/db mice had elevated hepatic glycogen levels, which was consistent with a previous report (Zhang et al., 2006b ). In addition, hepatic glycogen levels were further increased following treatment of db/db mice with FGF1 WT and FGF1 DHBS ( Figures S5A and S5C ). These observations demonstrate that chronic treatment of db/db mice with FGF1 WT and FGF1 DHBS lowers glucose levels by increasing insulin sensitivity to thereby manifest in elevated hepatic glycogen synthesis and storage.
Concluding Remarks
In conclusion, we show that the mitogenic and the metabolic activity of FGF1 can be uncoupled by surgically dampening FGF1-FGFR dimer stability through triple point mutations that diminish FGF1-HS affinity. The FGF1 DHBS sustained a loss in the ability to promote HS-dependent FGFR dimerization to a level that practically eliminated its mitogenic activity without compromising its metabolic function. To begin to gain insights into the impacts of FGF1-FGFR dimer stability on the choice of downstream intracellular pathways, we performed SILAC-based phosphoproteomics on 3T3L1 fibroblasts (a pre-adipocyte cell line) that were stimulated with FGF1 WT or FGF1 DHBS . Analysis of the phosphorylation of FGFR, its direct intracellular substrates, and further downstream molecules reveals a quantitative change in overall net phosphorylation and activation of FGFR and correspondingly weaker phosphorylation of downstream effector proteins between FGF1 WT -and FGF1 DHBS -treated cells ( Figure S6 ). These findings support the concept that different thresholds of receptor dimerization translate into different degrees of FGFR activation and downstream ''signal flow'' that in turn manifest in different cellular outcomes (i.e., mitogenesis versus metabolism) (Figure 7 ). The threshold model is further corroborated by a sideby-side comparison of the dimerization ability and mitogenic versus metabolic potentials of FGF1 WT , FGF1
DNT1
, FGF1 DHBS , and FGF1 DNT2 . As shown in Figure S7 , these four FGF1 molecule show a gradient of dimerization capacity in the following order:
. Consistent with our threshold model, as the dimerization strength decreases, the mitogenic potential dissipates first before a decrease in metabolic response can be observed. This trend between dimerization strength and the ensuing signaling outcome of FGF1 molecules further validates our ''threshold'' model ( Figure 7) . Like FGF1, FGF19 also possesses ''mixed'' metabolic and ''mitogenic'' activities although mitogenic activity of FGF19 is inferior to that of FGF1 ( Figure S2 ). In an effort to eliminate the undesired mitogenic effect of FGF19, Wu et al. (2010) at Amgen previously engineered a nonmitogenic FGF19 chimera wherein four residues from N terminus of FGF19 were replaced with the corresponding three residues from FGF21. This chimera was, however, shown to retain wild-type FGF19-like capacity to modulate glucose and bile acid metabolisms. The selective loss in mitogenic activity was attributed to a selective loss in binding of the chimera to FGFR4 that was proposed to mediate the mitogenic activity of FGF19. By contrast, the chimera retained the ability to bind FGFR1c, which was proposed to mediate metabolic actions of FGF19. However, based on our structural analysis, these N-terminal alterations would reduce interactions of FGF19 with both FGFR1c and FGFR4 such that reduced affinity and correspondingly reduced dimerization ability of this chimera underlies the non-mitogenic character of the chimera. Reminiscent of our results, Swanson et al. (2015) recently reported a therapeutic lectin that retains its full antiviral activity but is devoid of the undesired mitogenic activity. An engineered point mutation diminishes the glycan binding affinity of this lectin variant below the threshold necessary for formation of multivalent lectin-glycoprotein complexes that give rise to mitogenesis. However, the remaining glycan binding affinity of the variant was still sufficient to allow the mutated lectin to bind to viral glycan chains and hence exert antiviral effects. Hence, it appears that pleiotropic functions of other classes of proteins may also be manifestations of quantitative differences in the binding interactions with cognate binding partners. 
SPR Spectroscopy
Real-time biomolecular FGF1-heparin interactions were analyzed with a BIAcore 2000 system (GE Healthcare) in HBS-EP buffer (10 mM HEPES-NaOH, pH 7.4, 150 mM NaCl, 3 mM EDTA and 0.005% [v/v] polysorbate 20) at 25 C. A heparin chip was prepared by immobilizing biotinylated heparin (Sigma-Aldrich) on flow channels of a research grade streptavidin chip (GE Healthcare). The control flow channel was left blank. Increasing concentrations of FGF1 WT or FGF1 DHBS were injected over the chip. The heparin chip surface was regenerated by injecting 50 mL/min of 2.0 M NaCl in 10 mM sodium acetate, pH 4.5. The data were processed with BiaEvaluation software and the equilibrium dissociation constants (K D ) were calculated from fitted saturation binding curves. 
HPLC-MALS Analysis

BaF3 Cell Line Establishment and Stimulation
The murine pro-B BaF3 cell lines overexpressing FGFR1c wild-type was generated as described in the Supplemental Experimental Procedures. The cells were starved for 5 hr in FBS/IL-3 free RPMI 1640 medium followed by 10 min stimulation with FGF8a, FGF8b, or FGF8b F32A , respectively. Heparin was added to the cell culture medium to a final concentration of 5 mg/mL before stimulating the cells with the FGF ligands. BaF3 cell lines coexpressing FGFR1c and aKlotho or FGFR1c and bKlotho were established by infecting BaF3-FGFR1c cell line with lentivirus containing aklotho or bklotho gene. After infection, the cell lines were selected in medium containing both neomycin and hygromycin for 10 days to get stably infected cells. The stimulation was done as described above with FGF21, FGF23, or FGF19 as ligands.
Cell Culture, Adipocyte Differentiation, Glucose Uptake 3T3-L1 preadipocytes, NIH 3T3 cells, and rat hepatoma cell H4IIE (American Type Culture Collection) were cultured as described previously (Kharitonenkov et al., 2005; Kurosu et al., 2007) . Full details are described in the Supplemental Experimental Procedures.
Mitogenicity Assay
For mitogenicity assay in vitro, NIH 3T3 cells and rat hepatoma cell H4IIE were grown to reach the mid-logarithm time and transferred to a 96-well plate (5 3 10 3 /well), starved for 24 hr in DMEM without FBS, and stimulated with indicated concentration of FGF ligands for 48 hr. Next, the number of viable cells was determined by a Cell Growth Determination Kit (MTT-based) from Sigma-Aldrich. For mitogenicity assay in vivo, male C57BL/6J mice (2-month-old) were treated with vehicle (PBS), FGF1
WT , or FGF1 DHBS (0.5 mg/kg or 2.0 mg/kg body weight) every other day. After the indicated time (0.5 mg/kg, 3 month; 2.0 mg/kg, 1 month) of treatment, the mice were sacrificed and the liver tissues were collected for immunohistochemical staining and western blot assay of hepatic proliferation.
In Vivo Protocol
All experimental animals were from the Model Animal Research Center of Nanjing University, China or Jackson Laboratory, and the protocols used in these studies were approved by the Animal Care and Use Committee of Wenzhou Medical University, China or the University of Louisville, USA. The full details of animal feeding, grouping, and administration were described in the Supplemental Experimental Procedures.
Western Blot Analysis
The above-cultured 3T3-L1 adipocytes, NIH 3T3 cells, or H4IIE were starved for 12 hr, stimulated with a different dose of FGF1 WT and FGF1 DHBS for 20 min, and then lysed for future use. The liver and adipose tissues of the male db/db and db/m mice were collected and lysed after 28-day treatment with or without FGF1 WT and FGF1
DHBS
. Forty micrograms of lysate proteins from 3T3-L1 adipocytes, NIH 3T3, H4IIE cells, or liver tissues were separated using 8%-12% SDS-PAGE and electrotransferred onto a nitrocellulose membrane. The details of protein blots are described in the Supplemental Experimental Procedures.
RNA Extraction, cDNA Synthesis, and qRT-PCR Total RNA was extracted from liver and adipose tissues with TRIzol reagent (Invitrogen). The details of cDNA synthesis and qRT-PCR are described in the Supplemental Experimental Procedures. 
DNT2
have a gradually weaker intracellular signal due to weaker dimerization strengths. FGF1 DNT2 has almost no ability to bind/dimerize FGFR1c and hence produces no significant intracellular signaling. Bottom: shows the threshold of FGFR dimerization strength that determines the nature of signaling response. Sustained FGF-FGFR binding and dimerization is necessary to elicit strong intracellular signaling required to produce a mitogenic response (red trace) and weak FGF-FGFR binding and dimerization by a weak agonist leads to dampened intracellular signaling that is sufficient for a metabolic response (blue trace). See also Figures S6 and S7.
Tissue Preparation, Histopathological Evaluation, Immunohistochemistry Tissues were fixed overnight in 4% paraformaldehyde and embedded in paraffin. After deparaffinization and rehydration, the paraffin sections (5 mm) were subjected to H&E or immunohistochemical staining. For immunocytochemical staining, paraffin sections were stained with primary antibodies (rabbit polyclonal to PCNA [1:1,000], rabbit polyclonal to Ki67 [1:500]) from Abcam overnight at 4 C. After washing, sections were incubated with horseradish peroxidase conjugated secondary antibody against rabbit and developed with DAB (3,3-diaminobenzidine) developing system (Vector Laboratories), counterstained with hematoxylin and observed under light microscopy.
Metabolite Analysis
Hepatic lipid accumulation was evaluated by Oil Red O staining in accordance with the standard procedure. Triglyceride content in liver was measured using commercial kit (Cayman Chemicals) following the manufacturer's instructions. Glycogen in liver was evaluated by periodic acid-Schiff staining and a Glycogen Assay kit (Abcam) in accordance with the standard procedure or the manufacturer's instructions, respectively.
Phosphopeptide Quantitation Using SILAC The details of HILIC fractionation preparation, liquid chromatography-mass spectrometry (LC-MS), and protein identification and quantitation are described in the Supplemental Experimental Procedures.
Statistical Analysis
The in vitro experiments were performed three times with triplicate samples for each individual experiment. Data obtained from the animal study were obtained from five mice or six rats. All data were expressed as the mean ± SEM and subjected to statistical analysis by one-way or two-way ANOVA and Student's t test using statistical software NASDAQ: SPSS (SPSS Inc.). Furthermore, p < 0.05 was considered statistically significant. had full access to all the data in the study and take full responsibility for the integrity of the data and the accuracy of the data analysis.
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